Hims & Hers Health (HIMS) Scheduled to Post Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is scheduled to release its earnings data after the market closes on Monday, November 4th. Analysts expect Hims & Hers Health to post earnings of $0.06 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business’s revenue was up 51.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.03) EPS. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Trading Up 8.1 %

HIMS stock opened at $20.36 on Friday. The company’s 50-day moving average price is $18.01 and its 200 day moving average price is $18.09. Hims & Hers Health has a 52 week low of $5.97 and a 52 week high of $25.74. The company has a market cap of $4.37 billion, a P/E ratio of 254.53 and a beta of 1.06.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,334 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the transaction, the insider now owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 2,334 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20. Following the sale, the insider now directly owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 858,665 shares of company stock worth $15,148,890 in the last 90 days. 17.71% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Bank of America boosted their price target on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Piper Sandler reissued a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Truist Financial increased their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Finally, Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.